Skip to main content
. Author manuscript; available in PMC: 2014 Apr 19.
Published in final edited form as: Mol Cancer Ther. 2012 Jun 19;11(8):1799–1808. doi: 10.1158/1535-7163.MCT-11-1046

Figure 2.

Figure 2

Dose- and time-dependence of AT13387 treatment on HSP90 clients and KIT signaling in GIST cell lines. GIST882, GIST430, and GIST48 cells were treated with the indicated concentrations of AT13387 for 24 hours (A) or 250 nmol/L of AT13387 for 6 to 72 hours (B). Samples were run by SDS-PAGE and immunoblotted with the indicated antibodies.